Entities / Company
ADMA Biologics (United States).
company in Ramsey, United States
- Reports this week
- 0
- Active events
- 0
- Connections
- 34
What's happening
Gone quiet
No new reports in 90+ days-
ADMA Biologics manufactures FDA-approved biologics.Some support5 reports1 development inside
-
The CEO and Chairman of ADMA Biologics sold company shares in June 2025, causing a subsequent decline in stock price.Speculative1 report
-
Adma Biologics outperformed the S&P 500 this year, operating in the biomedical sector while investors tracked earnings via Zacks Rank.Some support10 reports
-
Director Steve Elms sold company shares of ADMA Biologics on July 23, 2025.Some support1 report
-
Brokerage firms assigned a strong positive bias to ADMA Biologics on July 24, 2025.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around ADMA Biologics (United States) this week
News at the entities that move ADMA Biologics (United States) most-
FDA StructuralAjay Devgn challenged a notice in the High Court while the FDA enforced state rules in Maharashtra.Moves ADMA Biologics (United States)
Connections
The 5 strongest of 34, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
The FDA formally regulates and approves ADMA's products and manufacturing processes, enabling its market operation.
-
Adam Grossman Structural
Adam Grossman serves as the President and CEO of ADMA Biologics, and his actions influence the company's stock performance.
-
Takeda Pharmaceutical Company Operational
ADMA Biologics and Takeda Pharmaceutical Company actively compete as leading players in the plasma-derived products sector.
-
Grifols (Germany) Operational
Both companies actively compete in the market for plasma-derived products.
-
Incepta Pharmaceuticals Mentioned together
The evidence only describes ADMA Biologics' membership in a specific industry group.
History
Events by the month they beganJune 2026
5 events- ADMA Biologics manufactures FDA-approved biologics.
- The CEO and Chairman of ADMA Biologics sold company shares in June 2025, causing a subsequent decline in stock price.
- Adma Biologics outperformed the S&P 500 this year, operating in the biomedical sector while investors tracked earnings via Zacks Rank.
- Director Steve Elms sold company shares of ADMA Biologics on July 23, 2025.
- Brokerage firms assigned a strong positive bias to ADMA Biologics on July 24, 2025.